Current and the near future medications for Alzheimer's disease: What can we expect from them?

Abstract

References

Rabins P , Blacker D , Cohen E : Practice Guideline for the treatment of Patients with Alzheimer's disease and other Dementias of late life. May 1997; (154) 5.

Doraiswamy M : Current Cholinergic Therapy for Symptoms of Alzheimer's disease. J of Primary Psychiatry. November 1996; 1-11.

Eisdorfer C , Olsen EJ : Management of patients with Alzheimer's disease and related dementias: The medical clinics of North America. July, 1994; (78) 4: Saunders company.

Davis KL , Thal LJ , Gamzu ER , et al: Tacrine Collaborative Study Group: A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med. 1992; 327: 1253-1259.

Farlow M , Gracon S , Hershey LA , et al: A controlled trial of tacrine in Alzheimer's disease. JAMA. 1992; 268: 2523-2529.

Knapp MJ , Knopman DS , Solomon PR , et al: A 30-week randomized controlled trial of high dose tacrine in patients with Alzheimer's disease. JAMA. 1994; 271: 985-991.

Forette F , Hoover T , Gracon S , et al: A double-blind, placebo-controlled, enriched population study of tacrine in patients with Alzheimer's disease. Eur J Neurology. 1995; 2: 1-10.

Foster NL , Petersen RC , Gracon S , et al: Tacrine 970-6 Study Group: An enriched-population, double-blind, placebo controlled, crossover study of tacrine and lecithin in Alzheimer's disease. Dementia. 1996; 7: 260-266.

Lyketsos CG , Corazzini K , Steele CD , et al: Guidelines for the use of tacrine in Alzheimer's disease: Clinical application and effectiveness. J Neuropsychiatry Clin Neurosci. 1996; 8: 67-73.

10.

Watkins PB , Zimmerman HJ , Knapp MJ , et al: Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA. 1994; 271: 992-998.

11.

Maning FC : Tacrine Therapy for the Dementia of Alzheimer's Disease. American Family Physician. 1994; 50: 819-823.

12.

Grossberg GT , Kumar V : Psychotherapeutic Agents in Older Adults: Clinic in Geriatric Medicine. February 1998; (14) 1: 130-130.

13.

Rogers SL , Doody R , Mohs R , et al: E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30-week phase III trial (abstract). Neurology. 1996; 46: 217-217.

14.

Rogers SL , Friedhoff LT , Apter JT , et al: The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 1996; 7: 293-303.

15.

Rogers SL, Friedhoff LT: Donepezil (E2020) produces long-term clinical improvement in Alzheimer's disease. Presented at the 4th International Nice/Springfield Symposium on Advances in Alzheimer's Therapy, April 10-14, 1996.

16.

Rosen WG , Mohs RC , Davis KL : A new rating scale for Alzheimer's Disease. Am J Psychiatry. 1984; 141: 1356-1364.

17.

Spencer MP , Folstein MF : The Mini-Mental State Examination. In: Keller PA, Ritt LG. Innovation in clinical practice: A Source Book. 1985; 4: 305-310.

18.

Folstein MF , Anthony JC , et al: Meaning of cognitive impairment in the elderly. J Am Geriat Soc. 1985; 33(4): 228-235.

19.

Anthony JC , LeResche L , Niaz U , et al: Limits of “Mini-Mental State” as a screening test for dementia and delirium among hospitalized patients. Psych Med. 1982; 12: 397-408.

20.

Folstein MF , Folstein S , Mchugh PR : Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psych Res. 1975; 12: 189-198.

21.

Aricept (donepezil hydrochloride) Package Insert. Eisai Inc. and Pfizer US Pharmaceuticals: June 1997.

22.

Gross JS , Shua-Haim JR : Aricept induced nightmares in Alzheimer's disease patients: Two case reports. Journal of the American Geriatrics Association (JAGS). 1998; 46(1): 119-120.

23.

Shua-Haim J , Shua-Haim V , Comsti E , et al: Aricept (donepezil): Caregivers and clinical impression. American Journal of Alzheimer's Disease. 1997; 12(6): 272-279.

24.

Katz S : Assessing self maintenance; activity of daily living, mobility, and instrumental activity of daily living. J Am Geriatr Soc. 1983; 31: 721-727.

25.

Lawton MP : Scale to measure competence in everyday activities. Psychopharm Bull. 1988; 24(4): 609-613.

26.

Wise J : Alzheimer's Disease drug not recommended. BMJ. October 1997; 315: 1037-1037.

27.

Abramowicz M : Ginkgo Biloba for Dementia. The Medical Letter. June 19, 1998; 40: 63-64.

28.

Bars LP , Katz MM , Berman N : A placebo-controlled, doubleblind, randomized trial of an extract of ginkgo biloba for dementia. JAMA. 1997; 278(16): 1327-1332.

29.

Knapp MJ , Knopman DS , Solomon PR : Ginkgo biloba safety and modestly improved dementia. ACP Journal Club: Therapeutics. May/June 1998: 70-70.

30.

Folstein MF , Schneider LS , Small GW : Alzheimer's disease: Current Progress, Future Promise. Patient Care. May 15, 1998: 156-176.

31.

Halliwell B , Gutteeridge JMC : Oxygen radicals in the nervous system. Trends Neurosci. 1985; 8: 22-26.

32.

Hara H , Kato H , Kogure K : Protective effect of alpha-tocopherol on ischemic neuronal damage in the gerbil hippocampus. Brain Res. 1990; 510: 335-335.8-8.

33.

Anderson DK , Waters TR , Means ED : Pretreatment with alpha tocopherol enhances neurologic recovery after experimental spinal cord compression injury. J Neurotrauma. 1988; 5: 61-67.

34.

Yoshida S , Busto R , Waston BD , et al: Postischemic cerebral lipid peroxidation in vitro: modification by dietary vitamin E. J Neurochem. 1985; 44: 1593-1601.

35.

Behl C , Davis J , Cole GM , et al: Vitamin E protects nerve cells from amyloid-beta protein toxicity. Biochem Biophys Res Commum. 1992; 1866: 944-950.

36.

Sano M , Ernesto C , Thomas RG : A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The New England Journal of Medicine. Year; 336(17): 1216-1223.

37.

Kumar V , Durai UN , Jobe T : Pharmacologic management of Alzheimer's disease. Clinics In Geriatric Medicine. 1998; 14(1): 129-146.

38.

Abramowicz M , Rizack MA : St. John's Wort. The Medical Letter on Drugs and Therapeutics. 1997; 39: 107-107.

39.

Nierenberg A : Should you take St. John's Wort? HealthNews. April 20, 1998: 5-5.

40.

Reisberg SF : Global deterioration scale (GDS) for assessment of primary degenerative dementia. Am J Psych. Sept. 1982; 139: 9-9.

41.

Reisberg B , Ferri SH , de Leon MJ , et al: The global deterioration scale for assessment of primary degenerative dementia. Am J Psych. 1982; 139: 1136-1139.

42.

Shua-Haim JR , Burnstein L , Gross JS : article name? The American Journal of Alzheimer's Care and Related Disorders & Research. 1995; 10(1): page #.

43.

B Staffeldt , et al: J Geriatr Psychiatry Neurol, 7 suppl 1:S47-S47,1994. K Lnde et al, BMJ, 3133:253, 1996. Vol. 39:Nov.21, 1997.

44.

Caldwell B , Watson R : An evaluation of psychological effects of se hormone administration in aged women: results after six months. J Gerontol. 1952; 7: 228-244.

45.

Yaffe K , Sawaya G , Liebergurg I , et al: Estrogen therapy in postmenopausal women. JAMA. 1999; 279: 688-695.

46.

Fillet H , Wenbreb H , Chgolst I , et al: Observations in a preliminary open trial of estradiol therapy for senile dementia—Alzheimer's type. Psychoneuroendocrinology. 1986; 11: 337-345.

47.

Honjo H , Ogino Y , Naitoh K , et al: An effect of conjugated estrogen to cognitive impairment in women with senile dementiaAlzheimer's type: a placebo-controlled double blind study. J Jpm Menopause Soc. 1993; 1: 167-171.

48.

Honjo H , Ogino Y , Naitoh K , et al: In vivo effects by estrone sulfate on the central nervous system-senile dementia: Alzheimer's type. J Steroid Biochem. 1989; 34: 521-525.

49.

McEwen BS , Wooley CS : Estradiol and progesterone relates neuronal structure and synaptic connectivity in adult as well as developing brain. Exp Gerontol. 1994; 29: 431-436.

50.

Gould E , Wooley CS , Frankfurt M , et al: Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood. J. Neurosci. 1990; 10: 1286-1291.

51.

Matsumoto A : Synaptogenic action of sex steroids in developing and adult neuroendocrine brain. Psychoneuroendocrinology. 1991; 16: 25-40.

52.

Luine VN : Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol. 1985; 89: 484-490.

53.

O'Malley CA , Hautamaski D , Kelley M , et al: Effects of ovariectomy and estradiol benzoate on high affinity choline uptake. Ach synthesis, and release from rat cerebral cortical synaptosomes. Brain Res. 1987; 403: 389-392.

54.

Gibbs RB , Hashash A , Johnson DA : Effects of estrogen on potassium-stimulated acetylcholine release in the hippocampus and overlying cortex of adult rats. Brain Res. 1997; 749: 143-146.

55.

Poirier MF , Loo H , Dennis T , et al: Platelet monoamine oxidase activity and plasma 3,4-dihydroxyphenylethylene glycol levels during the menstrual cycle. Neuropsychobiology. 1985; 14: 165-169.

56.

Klaiber EL , Broverman DM , Vogel W , et al: Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry. 1979; 36: 550-554.

57.

Aylward M : Plasma tryptophan levels and mental depression in postmenopausal subjects: effects of oral piperazine-oestrone sulphate. IRCS Med Sci. 1973; 1: 30-34.

58.

Thomson J , Maddock J , Aylward M , et al: Relationship between nocturnal plasma oestrogen concentration and free plasma tryptophan in peri-menopausal women. J Endocrinol. 1977; 72: 395-396.

59.

Behl C , Widmann M , Trapp T , et al: 17-Beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun. 1995; 216: 473-482.

60.

Goodman Y , Bruce AJ , Cheng B , et al: Estrogen attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J Neurochem. 1996; 66: 1836-1844.

61.

Roses AD : Apolipoprotein E genotyping in the differential diagnosis, not prediction of Alzheimer's disease. Ann Neurol. 1995; 38: 6-14.

62.

Yaffe K , Cauley J , Sands L , et al: Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. Arch Neurol. 1997; 54: 1110-1114.

63.

Honjo H , Ogino Y , Naitoh K , et al: An effect of conjugated estrogen to cognitive impairment in women with senile dementiaAlzheimer's type: A placebo-controlled double blind study. J Jpm Menopause Soc. 1993; 1: 167-171.

64.

SDZ-ENA-713 : Drugs Fur. 1997; 22(7): 805-805.

65.

O'Hara T , Tanaka K , Akahane N , et al: Different profile of SDA ENA 713 from other acetycholinesterase inhibitors to improve cholinergic deficit in basal forebrain-lesioned rats. Jpn J Pharmacol. 1996; 71(Suppl 1): Abst P-158.

66.

Sandoz announces promising findings from largest-ever global Alzheimer's study programme. Sandoz Press Release. July 26, 1996.

67.

Anand R , Gharabawi G , Enz A : Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's disease: An overview. J Drug Dev Clin Pract. 1996; 8(2): 109-116.

68.

Anand R , Gharabawi G , Hayes P : An overview of the development of SDZ ENA 713, a brain selective cholinesterase inhibitor. 4th Int Nice/Springfield Symp Adv Alzheimer Ther (April 10-14, Nice) 1996; 59-59.

69.

Anand R , Enz A : Clinical confirmation of pre-clinical attributes: The ADENA program. 5th Int Conf Alzheimer's Dis Relat Disord (July 24-29, Osaka) 1996, Abst 349-349.

70.

Anand R , Gharabawi G : Clinical development of Exelon (ENA713): The ADENA programme. J Drug Dev Clin Pract. 1996; 8(2): 117-122.

71.

Anand R , Harnan R , Gharabawi G : Therapeutic effect of Exelon in the treatment of patients with Alzheimer's disease. 49th Annu Meet Amer Acad Neurol (April 12-19, Boston) 1997. Abst S643-S643.001-001.

72.

Agid Y , Exelon Study Group : A multicentered, placebo controlled study on the efficacy and tolerability of SDZ ENA-713 in patients with mild-moderate dementia of the Alzheimer type. In prepxsaration.

73.

Becker R , Colliver J , Markwell S , et al: Effects of metrifonate on cognitive decline in Alzheimer disease: A double blind, placebo-controlled, six-month study. Alzh Dis Assoc Dis. 1998; (12): 54-57.

74.

Cyrus P , Ruzicka B , Gulanski B : The dose-related improvement by metrifonate of the cognitive performance of Alzheimer's disease patients. Neurology. 1998; 50: A49-A50.

75.

Cummings JL : Metrifonate: Overview of safety and efficacy. Pharmacotherapy. 1998; 18(2 pt 2): 43S-46S.

76.

Schmidt BH , Hinz BC , Blokland A , Vanderstaay FJ : Preclinical pharmacology of metrifonate: a promise for Alzheimer therapy. In RE Becker , I E Giacobin , P Robert , (eds.): Alzheimer's disease: From molecular biology to therapy. Boston: Birkhauser, 1996: 217-221.

77.

Cyrus PA , Farelow MR , Ruzicka BB , Gulanski B : The dose-related improvement by Metrifonate of the cognitive performance of Alzheimer's disease patient. From the 1998 Annual Meeting of the American Academy of Neurology, Poster Presentation #P02.012, April 28.

78.

Cummings J , Bieber F , Mas J , et al: Metrifonate in Alzheimer's disease: results of a dose finding study. In: K Iqbal , B Winblad , T Nishimura , et al (eds.): Alzheimer's disease: Biology, diagnosis and therapeutics. New York: John Wiley and Sons, 1997: 665-669.

79.

Crismon ML : Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer's disease. Pharmacotherapy. 1998; 18 (2 Pt 2): 47S-54S.

80.

Bayer Corporation. Data on file: 1997.

81.

Gelinas I , Gauthier S , Cyrus P , et al: The efficacy of metrifonate in enhancing the ability of Alzheimer's disease patients to perform basic and instrumental activities of daily living. Neurology. 1998; 50: A90-A91.

82.

Cummings J , Cyrus P , Ruzicka B , Gulanski B : The efficacy of metrifonate in improving the behavioral disturbances of Alzheimer's disease patients. Neurology. 1998; 50: A251-A251.

83.

Harvey AL : The pharmacology of galantamine and its analogues. Pharmac Ther. 1995; 68(1): 113-128.

84.

Westra P , et al: Pharmacokinetics of galantamine (a long-acting anticholinesterase drug) in anaesthetized patients. Br J Anaesth. 1986; 58: 1303-1307.

85.

Kewitz H , Wilcock G , Davis B : Galanthamine in Alzheimer's disease. In E Giacobini , R Becker , (eds.): Alzheimer Disease: Therapeutic Strategies. 1994; Birkhauser, Boston, p 140-144.

86.

Thomsen T , Kewitz H : Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci. 1990; 46: 1553-1558.

87.

Thomsen T , Kaden B , Fischer JP , et al: Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamie, physiostigmine and tacrine. Eur J Clin Chem Clin Biochem. 1991; 29: 487-492.

88.

Sweeney JE : A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice. Pharmacol Biochem Behav. 1988; 31: 141-147.

89.

Chopin P , Briley M : Effects of four non-cholinergic cognitive enhances in comparison with tacrine and galantamine on scopolamine-induced amnesia in rats. Pschyopharmacology. 1992; 106: 26-30.

90.

Sweeney JE : Effects of different doses of galantamine, a long-acting cholinesterase inhibitor, on memory in mice. Pschyopharmacology. 1990; 102: 191-200.

91.

Thomsen T . Galantamine hydrobromide in a long-term treatment of Alzheimer's disease. Dementia. 1990; 1: 46-51.

92.

Dewland PM , et al: Comparative bioavailability study of two oral formulations containing galanthamine in adult healthy volunteers. Simbec Research Ltd., August 1996; Study No. RD 256/20408.

93.

Dewland PM , et al: An interaction study of galanthamine with food after single oral administration of 10 mg galanthamine Hbr in healthy elderly male and female volunteers. Simbec Research Ltd., August 1996; Study No. RD 256/20899

94.

Bohets H : An in-vitro study on the cytochrome P-450 form(s) of human liver microsomes involved in the metabolism of galantamine. Janssen Research Foundation, August 1996; Non-clinical Pharmacokinetics Report R113675/FD2132.

95.

Mannens G : The plasma protein binding and the blood distribution of galantamine in man, dogs, rats, rabbits, and mice. Janssen Research Foundation, August 1996; Non-clinical Pharmacokinetics Report R113675/FD2198.

96.

Bicker U , et al: Pharmacokinetics of galantamine in humans and corresponding cholinesterase inhibition. Clin Pharmacol Ther. 1991; 50(4): 420-428.

97.

Thomsen T , Kewitz H : Galantamine treatment in senile dementia: a case report. In: Kewitz Tomse , Bickel , (eds.): Pharmacological Interventions on Central Cholinergic Mechanism in Senile Dementia. Munchen: Zuckschwerdt W Verlag, 1989; 238-241.

98.

Thomsen T , et al: Stereoselectivity of cholinesterase inhibition by galantamine and tolerance in humans. Eur J Clin Pharmacol. 1990; 39: 603-605.

99.

Dal-Bianco P , et al: Galantamine treatment in Alzheimer's disease. J of Neural Transm. Suppl. 1991; 33: 59-63.

100.

Rainer M , et al: Galantamine Hydrobromide in the treatment of senile dementia of the Alzheimer's type. In: Kewitz, Tomsen , Bickel , (eds.): Pharmacological Interventions in Central Cholinergic Mechanism in Senile Dementia. Munchen: Zuckschwerdt W Verlag, 1989; 233-237.

101.

Rainer M , et al: Galantamine in Alzheimer's disease—The identification of responders. Neuropsychopharmacology. 1994; 10(36/2): 174-112.

102.

Wilcock GK , et al: Galantamine and the treatment of Alzheimer's disease. Int J Geriatric Psychiatry. 1993; 8: 781-182.

103.

Kewitz H , et al: Galantamine in Alzheimer's disease. In E Giacobini , R Becker , (eds.): Alzheimer Disease: Therapeutic strategies. Birkerhauser Boston Inc.; Boston, Massachusetts, USA, 1994: 140-144.

104.

Kewitz H , et al: Galantamine, a selective non-toxic acetycholinesterase inhibitor is significantly superior over placebo in the treatment of SDAT. Neuropsychopharmacology. 1994; 10(35/2): 58-147.

105.

Drangel J : A placebo-controlled double-blind enriched de-challenge efficacy, safety and tolerability trial of galanthamine in mild to moderately severe primary degenerative dementia (Alzheimer's Disease-International trial. Ciba-Geigy Pharmaceuticals division, October 1993, Clinical Trial Report.

106.

Folstein MF , Schneider LS , Small GW , Williams TF : Alzheimer's disease: Current progress, future promise. Patient Care. May 15, 1998: 156-176.

107.

Stewart WF , Kwas C , Corrada , et al: Risk of Alzheimer's disease and duration of NSAID use. Neurology. 1997; 48: 628-632.

108.

Schenk BD , Rydel RE , May P , et al: Therapeutic approaches related to amyloid-B-peptide and Alzheimer's disease. J Med Chem. 1995; 38(21): 4141-4154.

109.

Kumar V , Durai NB , Jobe T : Pharmacologic management of Alzheimer's disease. Clin Geriatr Med. 1998; 14: 129-146. 2B1. Aisen P: Inflammation and alzheimer's disease. Mol chem Neuropathol. 1996; 28: 83-88.

110.

McGeer PL , Mehee E , Roger J , et al: Anti-inflammatory drugs and Alzheimer's disease. Lancet. 1990; 335: 1037-1037.

111.

McGeer PL , Harada N , Kimuva H , et al: Prevalence of dementia amongst elderly Japanese with leprosy: Apparent effect of chronic drug therapy. Dementia. 1992; 3: 146-149.

112.

Breitner JCS , Lau BA , Welsh KS , et al: Inverse association of anti-inflammatory treatments and Alzheimer's disease. Initial results of a co-twin control study. Neurology. 1994; 44: 227-232.

113.

Hla T , Neilson K : Human Cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA. 1992; 89: 7384-7388.

114.

Massferrer JL , Zweifel BS , Manning PT , et al: Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci USA. 1994; 91: 3228-3232.

115.

Meade EM , Smith WL , DeWitt DL : Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs. J Biol Chem. 1993; 268: 6610-6614.

116.

Mitchel JA , Akarasereenont P , Thiemermann C , et al: Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA. 1994; 90: 11693-11697.

117.

Aisen P , Davis KL : Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry. 1994; 151: 1105-1113.

118.

Troetel WM , Imbimbo BP : Overview of the development of eptastigmine, a long-acting cholinesterase inhibitor. In: Iqbal K , Winblad B , Nishimura T , et al, (eds): Alzheimer's Disease: Biology, Diagnosis and Therapeutics. 1997

John Wiley and Sons, Ltd.

P671 P676.

119.

Brufani M , Marta M , Ponponi M : Article? Eur J Biochem. 1986; 157: 115-120.

120.

Dawson GR , Bentley G , Draper F , et al: Article? Pharmacol Biochem Behav. 1991; 39: 865-891.

121.

Rupniak NMJ , Tye SJ , Brazil C , et al: Article? J Neurol Sci. 1992; 107: 246-249.

122.

Goldberg MR , Barchowsky A , McCrea J , et al: 2nd Int Springfield Symp Alzheimer Ther 1991: Abstract P22-P22.

123.

Imbimbo BP , Licine M , Schettino M , et al: Article? J Clin Pharmacol. 1995; 35: 285-290.

124.

Swift RH , Mant TG , Healtd A , et al: British Pharmacological Society. Joint Meeting with the Nordic Society, University of Southampton. 1991.

125.

Srarneck JJ , Block GA , Reines SA , et al: Article? Life Sci. 1995; 56: 319-326.

126.

Canal N , Imbimbo BP , Lucchelli PE : Article? Eur J Neurol. 1996; 3(Suppl 5): 238-238.

127.

Fisher A , Heldman E , Gurwitz D , et al: Selective signaling via novel muscarinic agonists: Implications for Alzheimer's disease treatments and clinical update. In: Giacobini E , Becker R , (eds.): Alzheimer Disease: Therapeutic Strategies. 1994

Birkhauser

Boston, 219-223.

128.

Schwarz RD , Callahan MJ , Davis RE , et al: Selective muscarinic agonists for Alzheimer disease treatment. In E Giacobini , R Becker , (eds.): Alzheimer's Disease: Therapeutic Strategies. Boston: Birkhauser, 1994; 224-228.

129.

Kubo T , Fukuda K , Mikami A , et al: Cloning, sequencing, and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature. 1986; 223: 411-416.

130.

Bonner TI , Buckley NJ , Young AC , et al: Identification of a family of muscarinic acetylcholine receptor genes. Science. 1987; 237: 527-532.

131.

Peralta EG , Ashkenazi A , Winslow JW , et al: Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J. 1987; 6: 3923-3929.

132.

Giacobini E : The cholinergic system in Alzheimer disease. In SM Aquilonius , P Gillberg (eds.): Progress Brain Res. Amsterdam: Elsevier, Boston: 1990; 321-332.

133.

Potter LT : Strategies for the treatment of Alzheimer's disease—cholinergic agonist. In ZS Khachaturian , JP Blass , (eds.): Alzheimer's Disease: New Treatment Strategies. New York: Marcel Dekker, 5766-5766.

134.

Caufield MP , Straughan DW , Cross AJ , et al: Cortical muscarinic subtypes and Alzheimer's disease. Lancet. 1982; 2: 1277-1277.

135.

Quirion R , Martel JC , Robitaille Y , et al: Neurotransmitter and receptor deficits in senile dementia of the Alzheimer's type. Canadian J Neurological Sci. 1986; 13: 503-510.

136.

Fisher A , Gurwitz D , Barak D , et al: Rigid analogs of acetylcholine can be M1-selective agonists: implications for a rational treatment strategy in Alzheimer's disease. Biorg Med Chem Lett. 1992; 2: 839-844.

137.

Farlow M , Gracon SI , Hershey A , et al: A controlled trial of tacrine in Alzheimer's disease. JAMA. 1992; 268: 2523-2529.

138.

Shannon HE , Bymaster FP , Calligaro DO , et al: Xanomeline: An efficacious and specific M1 receptor agonist-Preclinical update. In E Giacobini , R Becker (eds.): Alzheimer Disease: Therapeutic Strategies. Boston: Birkhauser, Boston, 1994; 229-233.

139.

Sauerberg P , Olesen PH , Nielsen S , et al: Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiaciazolyl)-1,2,5,6-tetrahydro-1-methlpridines. J Med Chem. 1992; 35: 2274-2283.

140.

Mitch CH , Bymaster FP , Calligaro DO , et al: Xanomeline: A potent and selective M1 agonists in vitro. Life Sci. 1993; 52: 550-550.

141.

Bymaster FP , Wong DT , Mitch CH , et al: Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232). J Pharmacol Exp Ther. 1994 (in press) STILL??

142.

Hoover TM : CI-979/RU 35926: A novel muscarinic agonist for the treatment of Alzheimer's disease. In E Giacobini , R Becker , (eds.): Alzheimer Disease: Therapeutic Strategies. Boston: Birkhauser, 1994; 238-243.

143.

Strolin BM , Dostert P : Monoamine oxidase, brain aging and degenerative disease. Biochemical Pharmacology. 1989; 38: 555-561.

144.

Reinikainen KJ , Paljarvi L , Halonen T , et al: Dopaminergic system and monoamine oxidase-B activity in Alzheimer's disease. Neurobiology of Aging. 1988; 9: 245-252.

145.

Nakamura S , Kawamata T , Akiguchi E , et al: Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropath. 1990; 80: 419-425.

146.

Kabins D , Gershohn S : Potential applications for monoamine oxidase B inhibitors. Dementia. 1990; 1: 323-348.

147.

Langston JW : Current theories on the cause of Parkinson's disease. J Neurol Psychiatr. 1989; June(suppl): 13-17.

148.

Sano M , et al: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med. 1997; 336: 1216-1222.

149.

Whitehouse PJ , Rabins PV : Geriatric Neurology. In J Burton , J Beck , S Ostwald , et al, (eds.): Yearbook of Geriatrics and Gerontology. 1998; 232-234.

150.

Piccinin GL , Finali G , Piccirilli M : Neuropsychological effects of L-deprenyl in Alzheimer's type dementia. Clinical Neuropharmacology. 1990; 13: 147-163.

151.

Tariot PN , Cohen RM , Sunderland T , et al: L-deprenyl in Alzheimer's disease. Arch Gen Psychiatry. 1987; 44: 427-433.

152.

Tariot PN , Sunderland T , Weingartener H , et al: Cognitive effects of L-deprenyl in Alzheimer's disease. Psychopharmacology. 1987; 91: 489-495.

153.

Monteverde A , Gnemmi P , Rossi F , et al: Selegiline in the treatment of mild to moderate Alzheimer's-type dementia. Clinical Therapeutics. 1990; 12: 315-322.

154.

Campi N , Todeschini OP , Scrabble L : Selegiline versus: Acetylcarnitine in the treatment of Alzheimer-type dementia. Clinical Therapeutics. 1990; 12: 306-314.

155.

Falsaperla A , Preti PAM , Oliani C : Selegiline versus oxiracetam in patients with Alzheimer-type dementia. Clinical Therapeutics. 1990; 132: 376-384.

156.

Mangoni A , Grassi MP , Frattola L , et al: Effects of a MAO-B inhibitor in the treatment of Alzheimer's disease. Eur Neurol. 1991; 31: 100-107.

157.

Goad DL , Davis CM , Liem P , et al: The use of selegiline in Alzheimer's patients with behavior problems. J Clin Psychiatry. 1991; 52: 342-345.

158.

Schneider LS , Pollack VE , Zemansky MF , et al: A pilot study of low-dose L-deprenyl in Alzheimer's disease. J Geriatric Psychiatry and Neurology. 1991; 4: 143-148.

159.

Nagel J, Yoo K, Pichard J, et al: Double-blind, placebo-controlled, parallel-group study to determine efficacy, safety, and tolerance of lazabemide in patients with Alzheimer's Disease (protocol N3654) and an open label treatment extension study of lazabemide in patients with Alzheimer's disease completing protocol N3654 (Protocol N14649) (GCR B164362).